Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7579473 | EXELIXIS INC | c-Met modulators and methods of use |
Aug, 2026
(2 years from now) | |
US11091439 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US8877776 | EXELIXIS INC | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(11 months from now) | |
US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US11091440 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(7 years from now) | |
US10034873 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2031
(7 years from now) | |
US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) | |
US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(9 years from now) | |
US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of d...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic